920509-32-6
- Product Name:Resmetirom
- Molecular Formula:C17H12Cl2N6O4
- Purity:99%
- Molecular Weight:435.226
Product Details:
CasNo: 920509-32-6
Molecular Formula: C17H12Cl2N6O4
Chinese Factory Supply High Purity Resmetirom 920509-32-6 Best Price
- Molecular Formula:C17H12Cl2N6O4
- Molecular Weight:435.226
Resmetirom 920509-32-6 Usage
Description |
Resmetirom is an orally administered, once-daily, small-molecule, liver-directed agonist that selectively activates thyroid hormone receptor beta (THR-β). By targeting the liver, resmetirom aims to modulate gene expression involved in hepatic fat metabolism and reduce lipotoxicity associated with NASH. |
Uses |
The primary therapeutic focus of Resmetirom is the treatment of NASH, a condition characterized by liver inflammation and fat accumulation. By selectively agonizing the thyroid hormone receptor-β, Resmetirom works to increase hepatic fat metabolism and mitigate lipotoxicity, which are critical factors in the progression of NASH. Data from completed clinical studies suggest that resmetirom effectively reduces hepatic fat content, improves liver enzymes, and decreases liver stiffness, indicating potential efficacy in treating NASH. Additionally, resmetirom demonstrates a favorable cardiovascular profile by reducing serum lipids, including LDL cholesterol. |
920509-32-6 Relevant articles
Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim and Meena B Bansalcor
touchREV Endocrinol. 2023 May; 19(1): 60–70.
Although there was not a significant difference in the number of patients achieving ≥1 stage improvement in fibrosis on resmetirom compared with placebo at the Week 36 liver biopsy, several key observations were made in assessing the impact of resmetirom on NASH and predictors of response.
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3- yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia
Kelly, Martha J.,Pietranico-Cole, Sherrie,Larigan, J. Douglas,Haynes, Nancy-Ellen,Reynolds, Charles H.,Scott, Nathan,Vermeulen, John,Dvorozniak, Mark,Conde-Knape, Karin,Huang, Kuo-Sen,So, Sung-Sau,Thakkar, Kshitij,Qian, Yimin,Banner, Bruce,Mennona, Frank,Danzi, Sara,Klein, Irwin,Taub, Rebecca,Tilley, Jefferson
, p. 3912 - 3923 (2014/06/09)
The beneficial effects of thyroid hormon...
920509-32-6 Process route
- 1581304-53-1
ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazineylidene)acetyl)carbamate
- 920509-32-6
2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile
Conditions | Yield |
---|---|
With potassium acetate; In N,N-dimethyl acetamide; at 120 ℃; for 2h; Large scale;
|
64% |
With potassium acetate; In N,N-dimethyl acetamide; at 120 ℃; for 3h; Inert atmosphere;
|
-
ethyl (E)-(2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazineylidene)acetyl)carbamate
- 920509-32-6
2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile
Conditions | Yield |
---|---|
With sodium acetate; acetic acid; at 20 - 120 ℃; for 1.5h;
|
61% |
920509-32-6 Upstream products
-
920509-28-0
6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-pyridazin-3(2H)-one
-
1581304-52-0
N-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)benzamide
-
1581304-53-1
ethyl (Z)-(2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazineylidene)acetyl)carbamate
-
1581304-47-3
N-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)acetamide
Relevant Products
-
Milvexian
CAS:1802425-99-5
-
2-Nitrodiphenylamine
CAS:119-75-5
-
Upadacitinib
CAS:1310726-60-3